What is the appropriate management for peripheral ulcerative keratitis?

Management of Peripheral Ulcerative Keratitis

Peripheral ulcerative keratitis (PUK) requires immediate systemic workup for underlying autoimmune disease and aggressive systemic immunosuppression with corticosteroids plus steroid-sparing agents, as this is a sight-threatening and potentially life-threatening condition that demands multidisciplinary management with rheumatology. 1, 2

Immediate Diagnostic Workup

Rule Out Infection First

• Obtain corneal cultures and smears before initiating immunosuppression if there is any suspicion of infectious etiology, particularly in patients with history of trauma, contact lens wear, or prior corneal surgery 3
• PUK can mimic infectious keratitis; bacterial superinfection must be excluded as corticosteroids will worsen infectious processes 3
• If clinical uncertainty exists about infectious versus immune-mediated etiology, initiate empiric antibiotics while awaiting culture results 3

Systemic Disease Evaluation

• Order comprehensive autoimmune panel: rheumatoid factor, anti-CCP antibodies, ANA, ANCA (c-ANCA and p-ANCA), anti-dsDNA, complement levels (C3, C4), ESR, CRP 4, 1
• PUK is highly associated with rheumatoid arthritis (most common), granulomatosis with polyangiitis, systemic lupus erythematosus, polyarteritis nodosa, microscopic polyangiitis, and relapsing polychondritis 3, 1, 2
• Critical caveat: The onset of PUK in a patient with known connective tissue disease may signal potentially lethal systemic vasculitis; untreated vasculitic PUK carries risk of premature death 1, 2
• Immediate rheumatology consultation is mandatory for coordinated systemic management 1

Medical Management Algorithm

Initial Systemic Immunosuppression

• Start high-dose systemic corticosteroids immediately once infection is ruled out: oral prednisone 1 mg/kg/day or IV methylprednisolone pulses (500-1000 mg daily for 3 days) for severe cases 4, 5, 6
• Do not rely on corticosteroids alone—early initiation of steroid-sparing immunosuppressive therapy is essential to prevent recurrence and allow corticosteroid taper 1, 6
• First-line steroid-sparing agents: methotrexate (15-25 mg weekly) or cyclophosphamide (IV pulses or oral) for severe/refractory cases 5, 6

Biologic Therapy for Refractory Cases

• Consider biologic agents when PUK is refractory to conventional immunosuppression (corticosteroids plus methotrexate or cyclophosphamide) 6
• Non-TNF biologics appear superior to anti-TNF agents: rituximab, tocilizumab, or abatacept showed better sustained response without requiring switching in a multicenter study of 34 patients 6
• Anti-TNF agents (adalimumab, infliximab) required switching in 48% of patients due to inadequate response, whereas non-TNF biologics did not require switching 6
• Rituximab is particularly effective for ANCA-associated vasculitis with PUK 6

Topical Therapy

• Topical corticosteroids (prednisolone acetate 1% every 1-2 hours initially) to control local inflammation 4, 5
• Topical lubricants and preservative-free artificial tears to support epithelial healing 3
• Avoid topical corticosteroids if infection has not been definitively ruled out 3

Surgical Management

Indications for Surgery

• Impending or frank corneal perforation requires urgent tectonic intervention 7, 5
• Progressive corneal thinning despite maximal medical therapy 5
• Corneal perforation with iris prolapse 4

Surgical Options (in order of invasiveness)

1. Cyanoacrylate glue application with bandage contact lens for small perforations (<2 mm) 4
2. Multilayer amniotic membrane graft for moderate thinning without perforation 5
3. Corneal patch graft for larger perforations or failed glue application 4
4. Superficial anterior lamellar keratoplasty (SALK) for extensive thinning; decentered large (8.5 mm) SALK can provide both tectonic support and acceptable visual outcomes 5

Critical Surgical Principles

• Systemic immunosuppression must be optimized before and maintained after surgery to prevent graft melting and recurrence 4, 5
• Rapid melting and reabsorption of amniotic membrane can occur if inflammation is not adequately controlled systemically 5
• Surgery alone without systemic immunosuppression will fail 4, 5

Monitoring and Follow-up

Clinical Response Indicators

• Reduced pain and ocular surface inflammation (scleritis, episcleritis resolution) 6
• Cessation of progressive corneal thinning and consolidation of infiltrate borders 3, 7
• Re-epithelialization of corneal defect 3, 7
• Reduced anterior chamber inflammation 7
• Stabilization or improvement in visual acuity 6

Follow-up Schedule

• Daily initially until stabilization confirmed 7
• Every 2-3 days during acute phase 7
• Expect increased inflammation in first 24-48 hours despite appropriate therapy—this does not indicate treatment failure 3, 7
• Modify therapy only if no improvement or stabilization within 48 hours 3, 7

Long-term Maintenance

• Transition to maintenance immunosuppression (azathioprine, mycophenolate mofetil, or continued biologic therapy) once acute inflammation controlled 5, 6
• Mean follow-up in biologic therapy studies showed sustained improvement at 23.7 months 6
• Regular ophthalmology and rheumatology co-management indefinitely 1

Critical Pitfalls to Avoid

• Never initiate corticosteroids without ruling out infection—this will worsen infectious keratitis and can lead to corneal perforation 3
• Never use corticosteroids alone without steroid-sparing agents—this leads to steroid dependence, recurrence upon taper, and systemic complications 1, 6
• Never perform surgery without optimizing systemic immunosuppression—grafts will melt without adequate inflammation control 4, 5
• Never assume PUK is isolated ocular disease—failure to diagnose and treat underlying systemic vasculitis can be fatal 1, 2
• Reducing or eliminating corticosteroids may temporarily increase inflammation and symptoms due to loss of immune suppression; this is not necessarily worsening infection and patients should be counseled about possible increased symptoms during taper 3